Lifecore Biomedical, Inc. LFCR Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

ADMA BiologicsADMA

$2.54M-45.9%

Thermo Fisher ScientificTMO

——

West Pharmaceutical ServicesWST

——

Halozyme TherapeuticsHALO

——

Other financials

Income statement

See full

Revenue$23.2M-36.4%

Gross profit$4.5M-68.1%

Operating income-$4.7M—

Net income-$15.0M-1,206%

EPS (diluted)-$0.43-1,333%

Balance sheet

See full

Cash & equivalents$20.8M+152%

Total debt$156.9M+1,310%

Total equity-$28.4M-2,229%

Total assets$225.5M-5.8%

Cash flow

See full

Operating cash flow$4.7M—

CapEx$1.1M-46.7%

Free cash flow$3.6M—

Valuation

See full

Market cap$196.92M-35.4%

Enterprise value$333.06M+8.3%

P/S1.6×+0.5×

Profitability

See full

Gross margin31.3%-1.4pp

Operating margin-14.5%-2.2pp

Net margin-30%—

FCF margin-36.4%—

Returns & leverage

See full

Return on equity-612.1%—

Debt / equity8.3×-1.5×

Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s payments to acquire property, plant, and equipment?: Lifecore Biomedical, Inc. (LFCR) reported payments to acquire property, plant, and equipment of $1.12M in Q1 2026.
How has Lifecore Biomedical, Inc.'s payments to acquire property, plant, and equipment changed year-over-year?: Lifecore Biomedical, Inc.'s payments to acquire property, plant, and equipment decreased by 46.7% year-over-year, from $2.1M to $1.12M.